Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively address portal hypertension induced complications of end-stage liver disease (ESLD). These complications include hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, both of which may lead to serious and life-threatening outcomes. Ocelot Bio has initiated a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 orphan drug designation in the treatment of hepatorenal syndrome. The company was founded by leading experts in therapeutic peptide development and is backed by a strong syndicate of investors including Venrock, RA Capital Management, and Vivo Capital. For more information, visit www.ocelotbio.com.
Something looks off?